As the world leader in researching, developing and manufacturing influenza vaccine, sanofi pasteur responded to the threat of pandemic influenza by being the first company to utilize industrial-scale manufacturing capabilities for a pandemic H5N1 vaccine. Sanofi pasteur’s unique expertise is combined with a high-priority pandemic research program designed to bring constant innovation to its candidate vaccine before a pandemic is declared.

Sanofi pasteur’s pragmatic approach resulted in its current ability to manufacture a vaccine against H5N1 pandemic influenza. Once a pandemic is declared, the company commits to produce as many doses of sanofi pasteur’s most advanced vaccine candidate as quickly as possible.

April 28, 2008
U.S. Government accepts $192 million of sanofi pasteur H5N1 bulk vaccine antigen for pandemic stockpile
Download the press release "U.S. Government accepts $192 million of sanofi pasteur H5N1 bulk vaccine antigen..."